Abstract 392P
Background
The real-world intracranial efficacy data of ceritinib at a dose of 450mg QD are still unavailable, thus this study aims to analyze the intracranial efficacy of ceritinib (450mg QD) in ALK-rearrangement NSCLC patients in China.
Methods
The intracranial and whole body efficacies [objective response rate (ORR) and disease control rate (DCR)] were respectively evaluated according to the Response Assessment in Neuro-Oncology (RANO) and Response Evaluation Criteria in Solid Tumors 1.1 (RECIST) standards, along with progression-free survival (PFS)/survival time and adverse events (AEs) obtained through follow-ups.
Results
A total of 57 ALK-rearrangement NSCLC patients with brain metastases (BM) were enrolled in this study. Among them, 53 patients experienced progression at baseline during or after prior crizotinib, and 24 patients received prior brain radiotherapy. The intracranial ORR and DCR were 73.7% and 93.0%, respectively. The whole body ORR and DCR were 87.7% and 98.2%, respectively. The median intracranial PFS and median whole body PFS in patients reached the endpoint were 8.75 months and 7.6 months, respectively; while those in all patients were not reached and predicted to be not evaluable (NE) (intracranial: 95% CI: 12.9-NE and whole body: 95% CI: 15.2-NE). The estimated 12-month event-free probabilities (EFP) of intracranial lesions was 68.1% ; and these of whole body lesions was 74.7%. Subgroup analysis showed the estimated 12-month EFP of intracranial lesions was relatively higher in patients with prior brain radiotherapy (93.8% vs 47.1%, P=0.0006). Additionally, we reported a 74-year-old female ALK-rearrangement NSCLC patient with BM achieved continuous response (intracranial PFS: 12.9 months) to ceritinib reduced to 150mg QD due to intolerable AE and administered for 7.5 months.
Conclusions
Ceritinib administered at a dose of 450mg QD to ALK-rearrangement NSCLC patients with BM in China demonstrates superior ORR and DCR, as well as PFS and EFP that are expected to be improved. Especially the estimated 12-month EFP of intracranial lesions was improved in patients with prior brain radiotherapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
West China Hospital, SIchuan Universtiy.
Funding
National Science Foundation of China (81700095, 81870034).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
133P - Which patient subgroup needs more attention in early treatment failure? A matched cohort study of treatment failure patterns in locally advanced gastric cancer
Presenter: Dong Wu
Session: e-Poster Display Session
134P - Effect of preoperative tumour under-staging on the long-term survival of patients undergoing radical gastrectomy for gastric cancer
Presenter: Mi Lin
Session: e-Poster Display Session
135P - Significance of lymphatic invasion in the indication for additional gastrectomy after endoscopic treatment
Presenter: Hirohito Fujikawa
Session: e-Poster Display Session
136P - Modified ypTNM staging classification for gastric cancer after neoadjuvant therapy: A multi-institutional study
Presenter: Wen-Wu Qiu
Session: e-Poster Display Session
137P - Clinical utility of circulating tumour DNA (ctDNA) in resectable gastric cancer (GC)
Presenter: Mikhail Fedyanin
Session: e-Poster Display Session
138P - Prognostic importance of dynamic changes in systemic inflammatory markers for patients with gastric cancer
Presenter: Ying-Qi Huang
Session: e-Poster Display Session
139P - An intraoperative model for predicting survival and deciding therapeutic schedules: A comprehensive analysis of peritoneal metastasis in patients with advanced gastric cancer
Presenter: Zhi-Yu Liu
Session: e-Poster Display Session
140P - Preoperative and postoperative C-reactive protein levels predict recurrence and chemotherapy benefit in gastric cancer
Presenter: Li-Li Shen
Session: e-Poster Display Session
141P - Low expression of CDK5RAP3 and UFM1 indicates poor prognosis in patients with gastric cancer
Presenter: Ning-Zi Lian
Session: e-Poster Display Session
142P - Prognostic analysis of patients with intra-abdominal infectious complications after laparoscopy and open radical gastrectomy for gastric cancer: A propensity score-matching analysis
Presenter: Si-Jin Que
Session: e-Poster Display Session